Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CorVue
binodenoson · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| binodenoson then adenosine | OTHER | binodenoson (experimental); adenosine (active comparator) |
| adenosine then binodenoson | OTHER | adenosine (active comparator); binodenoson (experimental) |
| adenosine then adenosine | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| binodenoson | DRUG | 30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo |
| adenosine | DRUG | 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute) |
Inclusion Criteria: * Able to understand and sign an informed consent form. Exclusion Criteria: * Women who are of childbearing potential. * Very low likelihood of coronary artery disease (by American Heart Association and American College of Cardiology standards). * Documented history of acute m...
Top 11 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Inclisiran, YMI024 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Viatris, Inc. | VTRS | 2 | PHASE3 | Selatogrel |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| Humacyte, Inc. | HUMA | 1 | PHASE2 | CTEV |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 2 | - | alirocumab |
| Bayer | BAYRY | 1 | PHASE1 | Nurandociguat |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7763505 |
Binodenoson is an investigational small molecule developed for use in assessing cardiac ischemia in patients with coronary artery disease. It is studied as a pharmacologic stress agent in cardiac imaging, where it helps evaluate blood flow to the heart muscle during diagnostic testing.
Binodenoson targets ADORA2A, the adenosine A2A receptor, and acts as an agonist at that receptor. By activating ADORA2A, the drug produces coronary vasodilation, which is the pharmacological effect used to simulate stress during cardiac imaging procedures.
Binodenoson is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer holds the development program for this small molecule adenosine A2A receptor agonist in the cardiovascular therapeutic area.
Binodenoson is in Phase 3 clinical development. It is an investigational agent and has not been approved by the FDA. Both of its recorded Phase 3 trials have been completed, and no trials are currently active.
Binodenoson has been studied in two completed Phase 3 trials: NCT00944970, which enrolled 578 participants, and NCT00944294, which enrolled 419 participants. Both were randomized, double-blind, controlled studies evaluating efficacy and safety in assessing cardiac ischemia in coronary artery disease patients.
The binodenoson clinical program enrolled a total of 997 participants across its two completed Phase 3 trials. Both studies were randomized, double-blind, and controlled, and enrolled adults aged 30 years and older with coronary artery disease.